Albany, NY -- (SBWIRE) -- 11/29/2016 -- Lymphoma is a common blood cancer type which develops when lymphocytes multiply in an uncontrolled manner. There are two types of lymphomas- Hodgkin's and non-Hodgkin's lymphoma, out of which non-Hodgkin's lymphoma is more common. Natural killer cell (NK) lymphoma is a type of non-Hodgkin's lymphoma. There are three types of NK cell lymphomas namely, extranodal, nasal type and aggressive NK cell lymphoma. Extranodal lymphomas occur in organs other than lymph nodes, hence called as extranodal lymphomas. Nasal type of NK cell lymphomas usually affects nasal areas and paranasal sinuses. Aggressive form of the lymphoma is a very fast growing cancer, because of which prognosis is difficult to study. NK cell lymphomas are also shown to be associated with Epstein Barr Virus (EBV).
Futuristic Market Analysis of Natural Killer Cell Lymphomas at: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2361
A study published in Journal of Rare Diseases in 2013, have shown that NK cell lymphomas are common in Asia, Latin America and Central America as compared to North America and Europe. As the prevalence is higher in developing economies, cost of the treatment will be a major barrier for market growth. But a strong pipeline and rising incidences of cancer is expected to support the market in the future.
Research and development activities has been impairedbecause of unpredictable prognosis and rare prevalence. Currently Cytoxan (cyclophosphamide), Procytox (cyclophosphamide), Adriamycin(doxorubicin), Oncovin(vincristine), Deltasone (prednisone) are widely used in chemotherapy. While radiation therapy is also practiced for treating the cancer. Various research institutes and corporates are also trying to discover new means to treat the cancer. These include Kirin Holdings Company, Mundipharma International Limited, Fred Hutchinson Cancer Research Center, Sun Yat-sen University, Seoul National University Hospital, University of Minnesota, Zhengzhou University, and M.D. Anderson Cancer Center. Study conducted by Zhengzhou University is currently under Phase IV trial which focuses in evaluation of gemcitabine, pegaspargase, cisplatin, and dexamethasone for chemotherapy.
Interpret the Current Market Analysis for Natural Killer Cell Lymphomas at: http://www.transparencymarketresearch.com/natural-killer-cell-lymphomas.html
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.